Short Interest in Healthcare Capital Acquisition Corp. (NASDAQ:HCAC) Decreases By 52.0%
by Jessica Moore · The Cerbat GemHealthcare Capital Acquisition Corp. (NASDAQ:HCAC – Get Free Report) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,507 shares, a decrease of 52.0% from the May 31st total of 3,137 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 61,874 shares, the short-interest ratio is presently 0.0 days.
Healthcare Capital Acquisition Price Performance
Shares of NASDAQ HCAC traded up $0.01 during mid-day trading on Tuesday, reaching $10.04. 370,894 shares of the company’s stock were exchanged, compared to its average volume of 102,978. The firm has a market capitalization of $374.38 million, a price-to-earnings ratio of 200.70 and a beta of 0.41. Healthcare Capital Acquisition has a 52-week low of $9.91 and a 52-week high of $10.08. The stock’s 50-day moving average is $10.01.
Healthcare Capital Acquisition (NASDAQ: HCAC) is a special purpose acquisition company (SPAC), commonly referred to as a blank‑check company, formed to raise capital through a public listing and pursue one or more business combinations. As a SPAC, Healthcare Capital Acquisition does not operate commercial businesses of its own; instead it holds funds in trust while identifying and negotiating a merger, acquisition or other business combination with an operating company, with a stated focus on opportunities in the healthcare sector.
The firm’s primary activities include sourcing and evaluating potential targets in healthcare and life sciences, structuring transactions, and completing a business combination that would result in the target becoming a publicly listed company.
Featured Articles
- Five stocks we like better than Healthcare Capital Acquisition
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?